Sacubitril-valsartan in Patients With Heart Failure.

This study is evaluating the effectiveness of sacubitril-valsartan (Entresto), a heart failure medication, in patients with heart failure and reduced pumping function (reduced ejection fraction). It tracks whether the drug improves heart function and reduces symptoms over time. **You may be eligible if...** - You are 18 or older - You have heart failure with a reduced ejection fraction (the heart pumps out 40% or less of blood with each beat) - Your heart failure symptoms are NYHA class II–IV (ranging from mild symptoms on exertion to symptoms at rest) **You may NOT be eligible if...** - You have severe kidney disease (GFR below 20 mL/min) - Your blood potassium is dangerously high (above 5.5 mmol/L) - You are pregnant or breastfeeding - You have an active infection - You have congenital (birth-related) heart disease, an autoimmune or connective tissue disorder, or severe liver disease Talk to your doctor to see if this trial is right for you.